RT Journal Article SR Electronic T1 Global epidemiology of hip fractures: a study protocol using a common analytical platform among multiple countries JF BMJ Open JO BMJ Open FD British Medical Journal Publishing Group SP e047258 DO 10.1136/bmjopen-2020-047258 VO 11 IS 7 A1 Sing, Chor-Wing A1 Lin, Tzu-Chieh A1 Bartholomew, Sharon A1 Bell, J Simon A1 Bennett, Corina A1 Beyene, Kebede A1 Bosco‐Lévy, Pauline A1 Chan, Amy Hai Yan A1 Chandran, Manju A1 Cheung, Ching-Lung A1 Doyon, Caroline Y A1 Droz-Perroteau, Cécile A1 Ganesan, Ganga A1 Hartikainen, Sirpa A1 Ilomaki, Jenni A1 Jeong, Han Eol A1 Kiel, Douglas P A1 Kubota, Kiyoshi A1 Lai, Edward Chia-Cheng A1 Lange, Jeff A1 Lewiecki, E Michael A1 Liu, Jiannong A1 Man, Kenneth K C A1 Mendes de Abreu, Mirhelen A1 Moore, Nicolas A1 O’Kelly, James A1 Ooba, Nobuhiro A1 Pedersen, Alma B A1 Prieto-Alhambra, Daniel A1 Shin, Ju-Young A1 Sørensen, Henrik T A1 Tan, Kelvin Bryan A1 Tolppanen, Anna-Maija A1 Verhamme, Katia M C A1 Wang, Grace Hsin-Min A1 Watcharathanakij, Sawaeng A1 Zhao, Hongxin A1 Wong, Ian C K YR 2021 UL http://bmjopen.bmj.com/content/11/7/e047258.abstract AB Introduction Hip fractures are associated with a high burden of morbidity and mortality. Globally, there is wide variation in the incidence of hip fracture in people aged 50 years and older. Longitudinal and cross-geographical comparisons of health data can provide insights on aetiology, risk factors, and healthcare practices. However, systematic reviews of studies that use different methods and study periods do not permit direct comparison across geographical regions. Thus, the objective of this study is to investigate global secular trends in hip fracture incidence, mortality and use of postfracture pharmacological treatment across Asia, Oceania, North and South America, and Western and Northern Europe using a unified methodology applied to health records.Methods and analysis This retrospective cohort study will use a common protocol and an analytical common data model approach to examine incidence of hip fracture across population-based databases in different geographical regions and healthcare settings. The study period will be from 2005 to 2018 subject to data availability in study sites. Patients aged 50 years and older and hospitalised due to hip fracture during the study period will be included. The primary outcome will be expressed as the annual incidence of hip fracture. Secondary outcomes will be the pharmacological treatment rate and mortality within 12 months following initial hip fracture by year. For the primary outcome, crude and standardised incidence of hip fracture will be reported. Linear regression will be used to test for time trends in the annual incidence. For secondary outcomes, the crude mortality and standardised mortality incidence will be reported.Ethics and dissemination Each participating site will follow the relevant local ethics and regulatory frameworks for study approval. The results of the study will be submitted for peer-reviewed scientific publications and presented at scientific conferences.